A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

(2010) E. L. Mayer et al.   ANNALS OF ONCOLOGY

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

(2010) W. Gradishar et al.   CANCER RESEARCH

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

(2010) Mark A. Socinski et al.   Journal of Thoracic Oncology

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

(2009) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2009) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY